Drug Target Review

OCTOBER 4, 2023

2 In response, DNA-damaging agents that could target the entire cell cycle received renewed attention as ADC payloads. Groundbreaking strategies like proteolysis-targeting chimeric molecules (PROTACs) are also being explored. 4 But the horizon of ADCs is expanding even further, with the design of complex payloads.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

The Premier Consulting Blog

APRIL 25, 2023

In the US, new small molecule drugs are developed under the requirements of Sections 505(b)(1) and 505(b)(2) of the FFDCA. ICH Harmonised Guideline M7(R1): Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. 8] US Food and Drug Administration (FDA).

FDA 52

FDA Animal Testing Pharmacokinetics Small Molecule 52

The Pharma Data

OCTOBER 14, 2020

Lanifibranor is believed to be the first drug candidate to be granted this status for the treatment of NASH since January 2015. has expanded its product portfolio to include Blueprint, a self-service, scientific visualization and analytics application for small molecule discovery. Dolmatics – U.K.-based based Dotmatics Ltd.

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Pharmaceutical Companies 52